Amyloidosis Testing & Counseling

A family living with hATTR amyloidosis

TESTING & COUNSELING:
 hattr amyloidosis

Alnylam Act®: Third-Party Genetic Testing and Counseling Programs Offered at No Charge

Alnylam is sponsoring no-charge third-party genetic testing and counseling for individuals who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis. The Alnylam Act® program was created to reduce barriers to genetic testing and counseling to help people make more informed decisions about their health.

 

The genetic testing service is available in the United States and Canada and the genetic counseling service is available in the United States. Learn more about what genetic testing and counseling are and how the process works here or by downloading the brochures below. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.

About hATTR Amyloidosis

hATTR amyloidosis is an inherited, progressive disease caused by a genetic mutation that results in the buildup of misfolded transthyretin (TTR) protein. This results in the formation of amyloid deposits in the heart, nerves, and gastrointestinal tract. hATTR amyloidosis affects approximately 50,000 people worldwide. Many people remain undiagnosed or misdiagnosed.

 

Symptoms of hATTR amyloidosis vary from person to person, depending on which organs or tissues are affected. As the disease progresses, symptoms may worsen (eg, numbness or tingling of the feet can result in the need to walk with an aid or use a wheelchair) and can lead to significant disability, decreased quality of life, and, in many instances, a shortened lifespan.

 

HCPs: Want more information about this disease to share with patients? Start Here

Privacy

While Alnylam provides financial support for this program, all tests and services are performed by independent third parties. Healthcare professionals must confirm that the patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient-identifiable information. Alnylam receives contact information for healthcare professionals who use this program.

Genetic testing and counseling may help to:
  • Identify risk of disease for patients and their family members
  • Shorten the time to diagnosis and prevent misdiagnoses
  • Help patients determine if they are eligible to participate in clinical trials
  • Provide information about support resources such as patient advocacy organizations

WANT TO ACT NOW?

For testing and instructions, click here.
You can also download the Alnylam Act® Brochures for hATTR Amyloidosis below.

For Healthcare Professionals

Download PDF >

For Patients

Download PDF >

SCIENCE OF RNAi

RNA interference marks a revolution in biology built on Nobel Prize-winning research.

Learn More >

THE BRIDGE

The BridgeTM is a program designed to help raise awareness of hereditary ATTR (hATTR) amyloidosis and promote education on the condition for patients and their families.

Visit Site >

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site

You are now leaving Alnylam.com

You are now being directed to another Alnylam website that contains information about specific treatment(s).

Proceed to Site

You are now leaving Alnylam.com

You are now being directed to another Alnylam website that contains information about specific treatment(s).

Proceed to Site